Prescribing Support
Relugolix for treating hormone-sensitive prostate cancer (NICE Technology Appraisal 995)

Indication	The treatment of hormone-sensitive prostate cancer: • Patients with advanced hormone-sensitive prostate cancer • Alongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer • Neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer
Formulation	120 mg tablet – 30 tablet pack size
Dosage	360 mg as a single dose, then 120 mg ONCE daily maintenance dose If treatment with relugolix is interrupted for more than 7 days, then treatment should resume with a 360 mg single dose followed by 120 mg ONCE daily
Drug interactions (N.B. this is not an exhaustive list. Consult the BNF and Summary of Product Characteristics (SPC) for full details)	**Strong cytochrome P450 3A4 (CYP3A4) and/or P-glycoprotein (P-gp) inducers** Co-administration is not recommended due to a reduction in plasma concentration and subsequent reduction in efficacy of Relugolix **Examples** Anticonvulsants (Carbamazepine, topiramate, phenytoin, phenobarbital, oxcarbazepine) Anti-infectives (Rifampicin, rifabutin, griseofulvin) St. John's Wort **Oral P-gp inhibitors** If concomitant use is required, Relugolix should be taken first and separate dosing of the P-gp inhibitor by at least 6 hours. **Examples** Anti-infectives (Azithromycin, erythromycin, clarithromycin, tetracycline) Anti-arrhythmics (Amiodarone, dronedarone) Anti-fungals (Voriconazole, ketoconazole) Antihypertensives (Carvedilol, verapamil) Ranolazine
Common adverse effects (N.B. this is not an exhaustive list. Consult the BNF and Summary of Product Characteristics for full details)	Anaemia; arthralgia; arthritis; asthenia; colitis; constipation; depression; diarrhoea; dizziness; gynaecomastia; headache; hot flush; hyperhidrosis; hypertension; insomnia; libido decreased; musculoskeletal discomfort; myalgia; nausea; pain; rash; weight increased May cause QT-interval prolongation (Frequency unknown)
Cautions	History or risk of QT-interval prolongation; risk factors for cardiovascular disease; risk factors for osteoporosis; moderate to severe renal impairment (No dose adjustment required).
Monitoring	No drug specific monitoring. As part of ongoing disease monitoring PSA will be the specialist's responsibility.

Prepared by: Terence Arnott (Principal Pharmacist for Cancer Services), West Suffolk Hospital NHS Foundation Trust
Reviewed by:
Version 1.0
Review date:

Patient Information	It is unknown whether relugolix or its metabolites are present in semen. If engaging in sexual intercourse with a person of childbearing potential then effective contraception must be used during treatment and for up to 2 weeks after the last dose of relugolix.
Specialist responsibilities	• The initial prescription will be provided by the hospital clinic after which prescribing should be undertaken in primary care. • Letters will be sent within contracted time of clinics appointments
GP responsibilities	• Take over ongoing prescribing of relugolix. • Familiarise themselves with relugolix by referring to the current versions of the SPC, BNF and this prescribing support document. • Consult specialist team via A&G promptly in there are any concerns about the patient that may affect treatment or if there are any concerns related to the prescribing of relugolix.

The most current edition of the British National Formulary (BNF) and the manufacturer's summary of product characteristics (SPC) should be consulted for full information on contraindications, cautions, warnings, drug interactions and side effects

Contacts		
West Suffolk Hospital		
Consultant Oncologist	Dr Alex Martin	
	Dr Cathryn Woodward	
	Dr Kent Yip	
Clinical Nurse Specialist	Claire Cross	

References

- Accord Healthcare. Summary of Product Characteristics - 0rgovyx. Available at https://www.accord-healthcare.com/ie/system/files/spc/orgovyx-SPC-product-information_en_v009.pdf. Accessed 21st November 2024.
- British National Formulary. 2024. Drug monograph – Relugolix. Available at https://bnf.nice.org.uk/drugs/relugolix/. Accessed 21st November 2024.
- National Institute for Health and Care Excellence. 2024. Technology Appraisal Guidance 995 – Relugolix for treating hormone-sensitive prostate cancer. Available at https://www.nice.org.uk/guidance/ta995. Accessed 21st November 2024.
- Pan Mersey Area Prescribing Committee. 2024. Relugolix for hormone-sensitive prostate cancer (NICE TA995). Available at https://www.panmerseyapc.nhs.uk/media/2676/relugolix_prostate.pdf. Accessed 21st November 2024.